Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 34

Publication Record

Connections

Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR
(2019) Blood 133: 1597-1606
MeSH Terms: Animals, Aorta, Cardiovascular Diseases, Endothelium, Fusion Proteins, bcr-abl, Humans, Imidazoles, Ischemia, Mice, Mice, Knockout, Platelet Adhesiveness, Protein Kinase Inhibitors, Pyridazines, Thrombotic Microangiopathies, Ventricular Dysfunction, von Willebrand Factor
Show Abstract · Added February 24, 2019
The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high rates of acute ischemic events. The pathophysiology responsible for these events is unknown. We hypothesized that ponatinib produces an endothelial angiopathy involving excessive endothelial-associated von Willebrand factor (VWF) and secondary platelet adhesion. In wild-type mice and ApoE mice on a Western diet, ultrasound molecular imaging of the thoracic aorta for VWF A1-domain and glycoprotein-Ibα was performed to quantify endothelial-associated VWF and platelet adhesion. After treatment of wild-type mice for 7 days, aortic molecular signal for endothelial-associated VWF and platelet adhesion were five- to sixfold higher in ponatinib vs sham therapy ( < .001), whereas dasatinib had no effect. In ApoE mice, aortic VWF and platelet signals were two- to fourfold higher for ponatinib-treated compared with sham-treated mice ( < .05) and were significantly higher than in treated wild-type mice ( < .05). Platelet and VWF signals in ponatinib-treated mice were significantly reduced by -acetylcysteine and completely eliminated by recombinant ADAMTS13. Ponatinib produced segmental left ventricular wall motion abnormalities in 33% of wild-type and 45% of ApoE mice and corresponding patchy perfusion defects, yet coronary arteries were normal on angiography. Instead, a global microvascular angiopathy was detected by immunohistochemistry and by intravital microscopy observation of platelet aggregates and nets associated with endothelial cells and leukocytes. Our findings reveal a new form of vascular toxicity for the TKI ponatinib that involves VWF-mediated platelet adhesion and a secondary microvascular angiopathy that produces ischemic wall motion abnormalities. These processes can be mitigated by interventions known to reduce VWF multimer size.
© 2019 by The American Society of Hematology.
0 Communities
1 Members
0 Resources
16 MeSH Terms
GTP cyclohydrolase I gene polymorphisms are associated with endothelial dysfunction and oxidative stress in patients with type 2 diabetes mellitus.
Wolkow PP, Kosiniak-Kamysz W, Osmenda G, Wilk G, Bujak-Gizycka B, Ignacak A, Kanitkar M, Walus-Miarka M, Harrison DG, Korbut R, Malecki MT, Guzik TJ
(2014) PLoS One 9: e108587
MeSH Terms: 3' Untranslated Regions, Adult, Aged, Alleles, Diabetes Mellitus, Type 2, Endothelium, Vascular, Female, GTP Cyclohydrolase, Genotype, Haplotypes, Humans, Linkage Disequilibrium, Male, Malondialdehyde, Middle Aged, Oxidative Stress, Polymorphism, Single Nucleotide, von Willebrand Factor
Show Abstract · Added March 31, 2015
BACKGROUND - The genetic background of atherosclerosis in type 2 diabetes mellitus (T2DM) is complex and poorly understood. Studying genetic components of intermediate phenotypes, such as endothelial dysfunction and oxidative stress, may aid in identifying novel genetic components for atherosclerosis in diabetic patients.
METHODS - Five polymorphisms forming two haplotype blocks within the GTP cyclohydrolase 1 gene, encoding a rate limiting enzyme in tetrahydrobiopterin synthesis, were studied in the context of flow and nitroglycerin mediated dilation (FMD and NMD), intima-media thickness (IMT), and plasma concentrations of von Willebrand factor (vWF) and malondialdehyde (MDA).
RESULTS - Rs841 was associated with FMD (p = 0.01), while polymorphisms Rs10483639, Rs841, Rs3783641 (which form a single haplotype) were associated with both MDA (p = 0.012, p = 0.0015 and p = 0.003, respectively) and vWF concentrations (p = 0.016, p = 0.03 and p = 0.045, respectively). In addition, polymorphism Rs8007267 was also associated with MDA (p = 0.006). Haplotype analysis confirmed the association of both haplotypes with studied variables.
CONCLUSIONS - Genetic variation of the GCH1 gene is associated with endothelial dysfunction and oxidative stress in T2DM patients.
1 Communities
1 Members
0 Resources
18 MeSH Terms
Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation.
Davis ME, Haglund NA, Tricarico NM, Matafonov A, Gailani D, Maltais S
(2015) ASAIO J 61: e1-4
MeSH Terms: Heart Transplantation, Heart-Assist Devices, Humans, Male, Middle Aged, Molecular Weight, Myxovirus Resistance Proteins, Postoperative Hemorrhage, Shock, Cardiogenic, von Willebrand Diseases, von Willebrand Factor
Show Abstract · Added January 20, 2015
All patients supported with continuous flow-left ventricular assist devices (CF-LVADs) develop acquired von Willebrand syndrome due to the loss of von Willebrand factor (vWF) high molecular weight (HMW) multimers and this phenomenon has been associated with clinical manifestation of bleeding diatheses. The precise timing of postoperative recovery of HMW multimers and correction of this condition after CF-LVAD explantation and heart transplantation is unknown. We sought to determine the specific timing of HMW multimer recovery by serially quantifying plasma vWF multimer ratios after CF-LVAD explant and orthotopic heart transplantation (OHT) in a patient implanted with a HeartWare ventricular assist device. Using densitometric analysis of multimer patterns, we demonstrated complete recovery of HMW multimers within the first few hours following CF-LVAD explant and OHT. These findings have critical implications in the context of perioperative bleeding diatheses in patients bridged to transplantation with a CF-LVAD.
0 Communities
1 Members
0 Resources
11 MeSH Terms
The NC2 domain of type IX collagen determines the chain register of the triple helix.
Boudko SP, Bächinger HP
(2012) J Biol Chem 287: 44536-45
MeSH Terms: Amino Acid Sequence, Collagen Type IX, Crystallography, X-Ray, Humans, Molecular Sequence Data, Protein Binding, Protein Folding, Protein Multimerization, Protein Stability, Protein Structure, Secondary, Protein Structure, Tertiary, von Willebrand Factor
Show Abstract · Added November 2, 2017
Precise mapping and unraveling the mechanism of interaction or degradation of a certain type of collagen triple helix requires the generation of short and stable collagenous fragments. This is a great challenge especially for hetero-trimeric collagens, where chain composition and register (stagger) are important factors. No system has been reported that can be efficiently used to generate a natural collagenous fragment with exact chain composition and desired chain register. The NC2 domain (only 35-50 residues) of FACIT collagens is a potent trimerization domain. In the case of type IX collagen it provides the efficient selection and hetero-trimerization of three distinct chains. The ability of the NC2 domain to determine the chain register of the triple helix is studied. We generated three possible sequence combinations (α1α1α2, α1α2α1, α2α1α1) of a type I collagen fragment (the binding region for the von Willebrand factor A3 domain) attached to the NC2 domain. In addition, two control combinations were produced that constitute homo-trimers of (α1)(3) or (α2)(3). For the hetero-trimeric constructs, α1α1α2 demonstrated a higher melting temperature than the other two. Binding experiments with the von Willebrand factor A3 domain revealed the homo-trimer of (α1)(3) as the strongest binding construct, whereas the homo-trimer of (α2)(3) showed no binding. For hetero-trimers, α1α1α2 was found to be the strongest binding construct. Differences in thermal stability and binding to the A3 domain unambiguously demonstrate that the NC2 domain of type IX collagen determines not only the chain composition but also the chain register of the adjacent triple helix.
0 Communities
1 Members
0 Resources
12 MeSH Terms
Effect of zymogen domains and active site occupation on activation of prothrombin by von Willebrand factor-binding protein.
Kroh HK, Bock PE
(2012) J Biol Chem 287: 39149-57
MeSH Terms: Binding, Competitive, Blood Coagulation, Carrier Proteins, Catalytic Domain, Enzyme Precursors, Fibrin, HEK293 Cells, Humans, Kinetics, Platelet Membrane Glycoproteins, Protein Binding, Protein Conformation, Protein Structure, Tertiary, Prothrombin, Recombinant Proteins, Staphylococcus aureus, Thermodynamics, Thrombin, Virulence Factors, von Willebrand Factor
Show Abstract · Added January 20, 2015
Prothrombin is conformationally activated by von Willebrand factor-binding protein (vWbp) from Staphylococcus aureus through insertion of the NH(2)-terminal residues of vWbp into the prothrombin catalytic domain. The rate of prothrombin activation by vWbp(1-263) is controlled by a hysteretic kinetic mechanism initiated by substrate binding. The present study evaluates activation of prothrombin by full-length vWbp(1-474) through activity progress curve analysis. Additional interactions from the COOH-terminal half of vWbp(1-474) strengthened the initial binding of vWbp to prothrombin, resulting in higher activity and an ∼100-fold enhancement in affinity. The affinities of vWbp(1-263) or vWbp(1-474) were compared by equilibrium binding to the prothrombin derivatives prethrombin 1, prethrombin 2, thrombin, meizothrombin, and meizothrombin(des-fragment 1) and their corresponding active site-blocked analogs. Loss of fragment 1 in prethrombin 1 enhanced affinity for both vWbp(1-263) and vWbp(1-474), with a 30-45% increase in Gibbs free energy, implicating a regulatory role for fragment 1 in the activation mechanism. Active site labeling of all prothrombin derivatives with D-Phe-Pro-Arg-chloromethyl ketone, analogous to irreversible binding of a substrate, decreased their K(D) values for vWbp into the subnanomolar range, reflecting the dependence of the activating conformational change on substrate binding. The results suggest a role for prothrombin domains in the pathophysiological activation of prothrombin by vWbp, and may reveal a function for autocatalysis of the vWbp·prothrombin complexes during initiation of blood coagulation.
0 Communities
1 Members
0 Resources
20 MeSH Terms
A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor.
Navarrete AM, Casari C, Legendre P, Marx I, Hu JR, Lenting PJ, Christophe OD, Denis CV
(2012) Blood 120: 2723-32
MeSH Terms: ADAMTS13 Protein, Animals, Antibodies, Monoclonal, Chlorides, Collagen, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Ferric Compounds, Fibrinolytic Agents, Hemorrhage, Humans, Metalloendopeptidases, Mice, Mice, Inbred C57BL, Mice, Knockout, Mutagenesis, Site-Directed, Mutation, Platelet Adhesiveness, Platelet Glycoprotein GPIIb-IIIa Complex, Thrombosis, von Willebrand Factor
Show Abstract · Added April 6, 2019
von Willebrand factor (VWF) is a promising target for developing antithrombotic drugs. The absence of accessible animal models impedes the study of specific human VWF (huVWF) targeting molecules in thrombosis. huVWF is not functional in the mouse because of a lack of interaction between huVWF and murine glycoprotein Ib. Using site-directed mutagenesis, we have replaced single or multiple amino acids in huVWF with their murine counterparts to eliminate species incompatibility. Using hydrodynamic injection, we have expressed the different chimeric VWF constructs into VWF(-/-) mice. Only huVWF with a complete murine A1 domain insertion was able to correct bleeding in vivo and form occlusive thrombi in mesenteric vessels after FeCl(3) treatment. Using this model, we tested the antithrombotic effect of monoclonal antibodies against huVWF, blocking its interaction with collagens (mAbs 203 and 505) or with glycoprotein IIbIIIa (mAb 9). The 3 mAbs inhibited the thrombotic process in arterioles of VWF(-/-) mice expressing huVWFmuA1. Inhibiting VWF-interaction with collagens was more potent, emphasizing the potential of such a target as an antithrombotic tool. Our results validate our murine model as a simple in vivo tool to evaluate anti-huVWF agents.
0 Communities
1 Members
0 Resources
MeSH Terms
T17b murine embryonal endothelial progenitor cells can be induced towards both proliferation and differentiation in a fibrin matrix.
Bleiziffer O, Horch RE, Hammon M, Arkudas A, Naschberger E, Rath S, Pryymachuk G, Beier JP, Hatzopoulos AK, Stürzl M, Kneser U
(2009) J Cell Mol Med 13: 926-35
MeSH Terms: Animals, Antigens, Differentiation, Cell Differentiation, Cell Hypoxia, Cell Proliferation, Cells, Cultured, Embryonic Stem Cells, Endothelial Cells, Endothelium, Vascular, Fibrin, Mice, Tissue Engineering, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2, von Willebrand Factor
Show Abstract · Added November 18, 2010
Endothelial progenitor cells (EPC) may enhance blood vessel formation in a variety of clinical settings such as ischaemia and tumour angiogenesis as well as in tissue-engineered matrices. In the present study, we cultured a murine endothelial progenitor cell line, T17b, in vitro in cell culture as well as in an FDA-approved fibrin matrix and investigated cell proliferation, differentiation and secretion patterns of the angiogenic growth factor VEGF under hypoxia and differentiation. We show that T17b EPC remain viable for at least 8 days in the fibrin matrix where they proliferate and form clusters including lumen-like structures. Proliferation in fibrin clots overlayed with basal medium (BM) was confirmed morphologically and immunohistochemically by positive Ki67 staining, indicating mitotic activity. Significant cell proliferation and Ki-67 expression were absent when cells were incubated with dibutyryl-cAMP and retinoic acid (RA). Incubation with dibutyryl-cAMP and RA stimulated the expression of the EPC differentiation markers von Willebrand Factor (vWF) and VEGF receptor 2 (VEGFR-2), indicating successful differentiation in the fibrin clot. EPC differentiation induced by dibutyryl-cAMP and RA was confirmed in 2-D chamber slide cultures by positive vWF immunostaining, which was absent in BM controls. EPC chamber slides also displayed positive vWF staining when exposed to hypoxia under BM conditions, indicating EPC activation and differentiation could also be induced by hypoxia. Taken together, T17b EPC secrete increased levels of VEGF when submitted to either hypoxia or differentiation and can be differentiated into mature endothelial cells not only in cell and matrigel cultures but also in a fibrin matrix that is FDA approved for clinical application.
1 Communities
1 Members
0 Resources
15 MeSH Terms
Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo.
Brantley-Sieders DM, Zhuang G, Vaught D, Freeman T, Hwang Y, Hicks D, Chen J
(2009) Mol Cancer Res 7: 615-23
MeSH Terms: Animals, Carcinoma, Lewis Lung, Cell Line, Tumor, Cell Movement, Cell Proliferation, Cell Survival, Coculture Techniques, Endothelial Cells, Melanoma, Experimental, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Nude, Neoplasms, Experimental, Neovascularization, Pathologic, Proto-Oncogene Proteins c-vav, Transplantation, Homologous, Tumor Burden, von Willebrand Factor
Show Abstract · Added May 23, 2013
Vav guanine nucleotide exchange factors modulate changes in cytoskeletal organization through activation of Rho, Rac, and Cdc42 small GTPases. Although Vav1 expression is restricted to the immune system, Vav2 and Vav3 are expressed in several tissues, including highly vascularized organs. Here, we provide the first evidence that Vav2 and Vav3 function within the tumor microenvironment to promote tumor growth, survival, and neovascularization. Host Vav2/3 deficiency reduced microvascular density, as well as tumor growth and/or survival, in transplanted B16 melanoma and Lewis lung carcinoma models in vivo. These defects were due in part to Vav2/3 deficiency in endothelial cells. Vav2/3-deficient endothelial cells displayed reduced migration in response to tumor cells in coculture migration assays, and failed to incorporate into tumor vessels and enhance tumor volume in tumor-endothelial cotransplantation experiments. These data suggest that Vav2/3 guanine nucleotide exchange factors play a critical role in host-mediated tumor progression and angiogenesis, particularly in tumor endothelium.
1 Communities
2 Members
0 Resources
19 MeSH Terms
Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin.
Kroh HK, Panizzi P, Bock PE
(2009) Proc Natl Acad Sci U S A 106: 7786-91
MeSH Terms: Binding, Competitive, Blood Coagulation, Carrier Proteins, Enzyme Activation, Humans, Hydrolysis, Kinetics, Molecular Conformation, Protein Binding, Protein Conformation, Protein Structure, Tertiary, Prothrombin, Staphylococcus aureus, Substrate Specificity, Trypsinogen, von Willebrand Factor
Show Abstract · Added January 20, 2015
Von Willebrand factor-binding protein (VWbp), secreted by Staphylococcus aureus, displays secondary structural homology to the 3-helix bundle, D1 and D2 domains of staphylocoagulase (SC), a potent conformational activator of the blood coagulation zymogen, prothrombin (ProT). In contrast to the classical proteolytic activation mechanism of trypsinogen-like serine proteinase zymogens, insertion of the first 2 residues of SC into the NH(2)-terminal binding cleft on ProT (molecular sexuality) induces rapid conformational activation of the catalytic site. Based on plasma-clotting assays, the target zymogen for VWbp may be ProT, but this has not been verified, and the mechanism of ProT activation is unknown. We demonstrate that VWbp activates ProT conformationally in a mechanism requiring its Val(1)-Val(2) residues. By contrast to SC, full time-course kinetic studies of ProT activation by VWbp demonstrate that it activates ProT by a substrate-dependent, hysteretic kinetic mechanism. VWbp binds weakly to ProT (K(D) 2.5 microM) to form an inactive complex, which is activated through a slow conformational change by tripeptide chromogenic substrates and its specific physiological substrate, identified here as fibrinogen (Fbg). This mechanism increases the specificity of ProT activation by delaying it in a slow reversible process, with full activation requiring binding of Fbg through an exosite expressed on the activated ProT*.VWbp complex. The results suggest that this unique mechanism regulates pathological fibrin (Fbn) deposition to VWF-rich areas during S. aureus endocarditis.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP.
Cleator JH, Zhu WQ, Vaughan DE, Hamm HE
(2006) Blood 107: 2736-44
MeSH Terms: Calcium Signaling, Cell Line, Cyclic AMP, Endothelium, Vascular, Exocytosis, Humans, Kinetics, P-Selectin, Peptide Hydrolases, Protein Transport, Receptor, PAR-1, Receptor, PAR-2, Receptors, Cell Surface, Signal Transduction, Thrombin, Umbilical Veins, von Willebrand Factor
Show Abstract · Added January 20, 2015
Thrombin-mediated endothelial-cell release of von Willebrand factor (VWF) and P-selectin functionally links protease-activated receptors (PARs) to thrombosis and inflammation. VWF release can be stimulated by both Ca2+ and cAMP, and, although both VWF and P-selectin are found in Weibel-Palade bodies (WPBs), we found that their release could be differentially regulated. In these studies, human umbilical vein endothelial cells stimulated with cAMP or PAR2-AP led to a delayed release of VWF and significantly less P-selectin release compared with histamine, thrombin, or PAR1-AP. Dose-response studies revealed that PAR2-AP was significantly less efficacious in promoting the release of P-selectin compared with VWF. PAR2-AP-induced robust stimulation of intracellular Ca2+ coupled with a significantly greater inhibitory effect of calcium chelation on release of VWF compared with cell-surface expression of P-selectin, suggests an additional Ca2+-independent pathway involved in release of P-selectin. PAR2-AP failed to increase global cAMP levels; however, inhibition of protein kinase A led to a significant attenuation of PAR2-AP-mediated release of VWF. Confocal microscopy studies revealed that PAR2 and forskolin caused preferential release of a population of Weibel-Palade bodies (WPBs) consisting of only VWF. Thus, WPBs are pharmacologically and morphologically heterogeneous, and distinct granule populations are susceptible to differential regulation.
0 Communities
1 Members
0 Resources
17 MeSH Terms